Bio View

Bio View Debt/EBITDA

The Total Debt to EBITDA Ratio of Bio View (BIOV.TA) as of Oct 19, 2026 is -0.35. In the previous year, Total Debt to EBITDA Ratio was -0.90 — a change of -60.78% (higher).

Debt/EBITDA

-0.35

YoY

-60.78%

Last updated:

Total Debt to EBITDA Ratio of Bio View is 2025 -0.35 . Total Debt to EBITDA Ratio of Bio View was 2024 -0.90 . It decreases by -60.78% higher compared to the previous year.

The Bio View Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2019
0.62 ILS
Jan 1, 2020
0.83 ILS
Jan 1, 2021
1.32 ILS
Jan 1, 2022
2.07 ILS
Jan 1, 2023
2.48 ILS
Jan 1, 2024
-0.90 ILS
Jan 1, 2025
-0.35 ILS
The Bio View Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.35-60.78%
-0.90-136.19%
2.48+20.06%
2.07+56.95%
1.32+57.68%
0.83+35.41%
0.62—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Bio View Stock analysis

What does Bio View do? Bio View Ltd, based in Rehovot, Israel, operates in the Health Care sector, specializing in the research, development, marketing, and sales of advanced imaging systems. The company manufactures and services the Duet workstation, an automated cell diagnostic system used in cytology, hematology, and pathology laboratories for detecting and analyzing abnormal cells. It also offers the ALLEGRO and ACCORD workstations for specialized applications in cancer diagnosis, minimal-residual disease monitoring, and FISH-based analyses in cytogenetics and oncology. Bio View is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio View stock

Total Debt to EBITDA Ratio of Bio View is -0.35 in 2025.

Total Debt to EBITDA Ratio of Bio View changed from -0.90 to -0.35, representing a -60.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Bio View since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Bio View with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Bio View

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Bio View